Greg Galler

Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro

Neutralizing antibody response during acute and chronic hepatitis C virus infection

Evidence for a functional RNA element in the hepatitis C virus core gene

Mouse models of acute and chronic hepacivirus infection

Proteomics of HCV virions reveals an essential role for the nucleoporin Nup98 in virus morphogenesis

Predicting outcome in severe ulcerative colitis.

Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin

Infliximab for acute, not steroid-refractory ulcerative colitis

SEC14L2 enables pan-genotype HCV replication in cell culture

Genetic variation in IL28B and spontaneous clearance of hepatitis C virus

Infliximab in the Treatment of Severe, Steroid-Refractory Ulcerative Colitis: A Pilot Study

Treatment triumphs

Serum Cholesterol and Statin Use Predict Virological Response to Peginterferon and Ribavirin Therapy†,‡

Unravelling the pathogenesis of inflammatory bowel disease

Long-term Outcome of Treatment with Intravenous Cyclosporin in Patients With Severe Ulcerative Colitis

Treatment responses in Asians and Caucasians with chronic hepatitis C infection

Evaluation of the clinical course of acute attacks in patients with ulcerative colitis through the use of an activity index

Guidelines for the management of inflammatory bowel disease in adults

Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis

Inflammatory bowel disease: clinical aspects and established and evolving therapies

Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee

Shared and Distinct Functions of Type I and Type III Interferons

Randomized Trial of Peginterferon alfa-2b and Ribavirin for 48 or 72 Weeks in Patients with Hepatitis C Virus Genotype 1 and Slow Virologic Response

Inhibition of α-helix-mediated protein–protein interactions using designed molecules

A randomised dose finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis

Infliximab for patients with refractory ulcerative colitis

A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease

Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43

The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study

The role of resistance in HCV treatment

Preliminary Study of Two Antiviral Agents for Hepatitis C Genotype 1

Diagnosis, management, and treatment of hepatitis C: An update # † ‡

Early Mucosal Healing With Infliximab Is Associated With Improved Long-term Clinical Outcomes in Ulcerative Colitis

Role of the Microbiota in Immunity and Inflammation

Cyclosporine and Infliximab as Rescue Therapy for Each Other in Patients With Steroid-Refractory Ulcerative Colitis

Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

Metazoan MicroRNAs

Nicotine inhibits the in vitro production of interleukin 2 and tumour necrosis factor-α by human mononuclear cells

A Computationally Designed Inhibitor of an Epstein-Barr Viral Bcl-2 Protein Induces Apoptosis in Infected Cells

Ulcerative colitis

Pegylated Interferon‐α‐2a plus Ribavirin for Treatment‐Naive Asian Patients with Hepatitis C Virus Genotype 1 Infection: A Multicenter, Randomized Controlled Trial

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer

Inflammatory Bowel Disease

The Impact of the Gut Microbiota on Human Health: An Integrative View

Colectomy Rate Comparison After Treatment of Ulcerative Colitis With Placebo or Infliximab

Gastrointestinal infections and the development of irritable bowel syndrome

Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination

Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis1 1Gert Van Assche, Severine Vermeire, Geert D’Haens, and Paul Rutgeerts have been instrumental in the design of the study, trial management, data analysis, and writing the paper. Maja Noman had a major contribution in the clinical ambulatory follow-up of the patients in the trial. Martin Hiele followed cyclosporine levels and adjusted drug doses of patients in the trial and provided statistical advice. Katrien Asnong was the study coordinator and had a major share in data analysis. Joris Arts analyzed safety data and followed patients clinically during the trial. Andre D’Hoore and Freddy Penninckx performed the surgical interventions in patients failing the trial and substantially contributed in evaluating patients for colectomy.

Update on hepatitis C virus resistance to direct-acting antiviral agents

Medical therapy for ulcerative colitis 2004

Recognition of Commensal Microflora by Toll-Like Receptors Is Required for Intestinal Homeostasis

Mechanisms of Disease: pathogenesis of Crohn's disease and ulcerative colitis

Ulcerative colitis

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

A diverse range of gene products are effectors of the type I interferon antiviral response

Inflammatory Bowel Disease

Global control of hepatitis C: where challenge meets opportunity

Ulcerative Colitis Practice Guidelines in Adults: American College of Gastroenterology, Practice Parameters Committee

Azathioprine or 6-Mercaptopurine Before Colectomy for Ulcerative Colitis Is Not Associated With Increased Postoperative Complications

Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis

Treatment of ulcerative colitis by feeding with germinated barley foodstuff: first report of a multicenter open control trial

Interferon-β-1a for the Treatment of Steroid-Refractory Ulcerative Colitis: A Randomized, Double-Blind, Placebo-Controlled Trial

Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial

A microbial symbiosis factor prevents intestinal inflammatory disease

The HCV Life Cycle: In vitro Tissue Culture Systems and Therapeutic Targets

Repertoires of Autophagy in the Pathogenesis of Ocular Diseases

Understanding the hepatitis C virus life cycle paves the way for highly effective therapies

Ipilimumab-induced acute severe colitis treated by infliximab

Diversity, stability and resilience of the human gut microbiota

Successive Treatment With Cyclosporine and Infliximab in Steroid-Refractory Ulcerative Colitis

Quantitive Cytokine mRNA Expression Profiles in the Colonic Mucosa of Patients with Steroid Naïve Ulcerative Colitis During Active and Quiescent Disease

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

Retreatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

Boceprevir for Untreated Chronic HCV Genotype 1 Infection

American Gastroenterological Association Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease

HCV and the hepatic lipid pathway as a potential treatment target

Guidelines for the management of inflammatory bowel disease in adults

Sympathetic Neural Mechanisms of Cyclosporine-Induced Hypertension*

Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis

Hepatitis C Virus RNA Functionally Sequesters miR-122

Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19

Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles

Characterization of nonprimate hepacivirus and construction of a functional molecular clone

Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus

Modeling hepatitis C virus infection using human induced pluripotent stem cells

[American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease].

Immune-Related Adverse Events Associated with Immune Checkpoint Blockade

A bacterial Argonaute with noncanonical guide RNA specificity

Infliximab as Rescue Therapy in Severe to Moderately Severe Ulcerative Colitis: A Randomized, Placebo-Controlled Study

Cellular cofactors affecting hepatitis C virus infection and replication

Cyclosporine A-induced hypertension involves synapsin in renal sensory nerve endings

Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs

A Review of Activity Indices and Efficacy End Points for Clinical Trials of Medical Therapy in Adults With Ulcerative Colitis

Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders

European evidence-based Consensus on the management of ulcerative colitis: Current management

MyD88 signaling in nonhematopoietic cells protects mice against induced colitis by regulating specific EGF receptor ligands

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial

Tacrolimus (FK506) for induction of remission in refractory ulcerative colitis

A critical review of cyclosporine therapy in inflammatory bowel disease

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

Cyclosporine in Severe Ulcerative Colitis Refractory to Steroid Therapy

Travel and Travelers' Diarrhea in Patients with Irritable Bowel Syndrome

Impact of weight-based ribavirin with peginterferon alfa-2b in african americans with hepatitis C virus genotype 1

2016 LONG-TERM OUTCOMES FOLLOWING COMBINATION TREATMENT WITH BOCEPREVIR PLUS PEG-INTRON/RIBAVIRIN (P/R) IN PATIENTS WITH CHRONIC HEPATITIS C, GENOTYPE 1 (CHC-G1)